TGFB1 and neoplasm: More importantly, the inhibition of HSF1 nuclear translocation from this TRPV1 blockade distinctly attenuates TGFβ1 for effective decomposition of ECM to improve the infiltration of antitumor therapeutics (e.g. anti-PD-L1 antibody, aPD-L1) and immune cells into highly fibrotic and immunosuppressive tumors such as PDAC model, eventually achieving synergistic thermo-immunotherapy against both subcutaneous and orthotopic tumor models through the reinvigorated immune responses and alleviated immunosuppression.